Xilio Therapeutics, Inc. (XLO): who owns it and who trades it
As of Nov 16, 2026, XLO insiders reported 2 open-market sales worth $5.7K and 1 purchase worth $43.9K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher James Frankenfield (CFO), with $4.5K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Xilio Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns XLO
25 funds and institutions reported XLO shares worth $26.4M at the end of Q2 2026, about 48% of the company. The largest holder is Bain Capital Life Sciences Investors, LLC with 11.5%.
Funds and institutions (13F) 48%Everyone else 52%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 | 11.48% | $6.4M | No change |
| Orbimed Advisors LLC | 592,300 | 10.24% | $5.7M | New |
| Frazier Life Sciences Management, L.P. | 422,505 | 7.31% | $4M | No change |
| Stonepine Capital Management, LLC | 225,994 | 3.91% | $2.2M | +252% |
| Vanguard Capital Management LLC | 178,517 | 3.09% | $1.7M | +44% |
| Sio Capital Management, LLC | 152,464 | 2.64% | $1.5M | No change |
| Adage Capital Partners Gp, L.l.c. | 111,541 | 1.93% | $1.1M | New |
| Merck & Co., Inc. | 105,982 | 1.83% | $1M | No change |
| Renaissance Technologies LLC | 64,153 | 1.11% | $615K | +29% |
| Morgan Stanley | 56,954 | 0.98% | $546K | -1% |
| Geode Capital Management, LLC | 39,055 | 0.68% | $374K | +5% |
| Citadel Advisors LLC | 25,950 | 0.45% | $249K | New |
| Vanguard Fiduciary Trust Co | 22,594 | 0.39% | $216K | -21% |
| Bridgeway Capital Management, LLC | 17,544 | 0.30% | $168K | New |
| Two Sigma Investments, LP | 14,544 | 0.25% | $139K | New |
| Velan Capital Investment Management LP | 14,285 | 0.25% | $137K | No change |
| Gsa Capital Partners LLP | 13,590 | 0.24% | $130K | -20% |
| State Street Corp | 13,311 | 0.23% | $128K | No change |
| Prelude Capital Management, LLC | 11,600 | 0.20% | $111K | New |
| BlackRock, Inc. | 8,757 | 0.15% | $83.9K | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, XLO insiders reported $43.9K of open-market purchases and $5.7K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | James Samuel Shannon | Director | Purchase | 5,000 | $8.79 | $43.9K | Form 4 |
| Jan 2, 2026 | Kevin M. Brennan | Vice president | Sale | 1,826 | $0.64 | $1.2K | Form 4 |
| Jan 2, 2026 | Christopher James Frankenfield | CFO | Sale | 7,030 | $0.64 | $4.5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| James Samuel Shannon | Director | $43.9K | – | Mar 26, 2026 |
| Christopher James Frankenfield | Chief Financial Officer | – | $4.5K | Jan 2, 2026 |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | – | $1.2K | Jan 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
XLO short interest
382,761 XLO shares are sold short. Over the last 12 reports the number of shares short went up 123%.
As of Oct 30, 2026, 382,761 XLO shares were sold short, down 4.4% from the report before. At the average daily volume of 18,852 shares, buying them all back would take about 20.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 382,761 | – | -4% | 18,852 | 20.3 |
| Oct 15, 2026 | 400,316 | – | -2% | 9,727 | 41.2 |
| Sep 30, 2026 | 410,050 | 7.09% | -1% | 9,210 | 44.5 |
| Sep 15, 2026 | 412,963 | 7.14% | -1% | 11,055 | 37.4 |
| Aug 31, 2026 | 418,277 | 7.23% | -1% | 10,705 | 39.1 |
| Aug 14, 2026 | 421,921 | 7.30% | -1% | 13,340 | 31.6 |
| Jul 31, 2026 | 425,882 | 7.37% | +59% | 34,680 | 12.3 |
| Jul 15, 2026 | 268,180 | 4.64% | +54% | 59,349 | 4.5 |
| Jun 30, 2026 | 174,619 | 3.02% | +1% | 47,868 | 3.6 |
| Jun 15, 2026 | 173,470 | 3.00% | +5% | 24,458 | 7.1 |
| May 29, 2026 | 165,274 | 2.86% | -4% | 30,465 | 5.4 |
| May 15, 2026 | 171,370 | 2.96% | +5% | 95,033 | 1.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Xilio Therapeutics company events
Xilio Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jun 12, 2026LeadershipIn order to achieve a more equal balance of director membership among the three classes of the board of directors of Xilio Therapeutics, Inc. in accordance with the Company’s Restated Certificate of Incorporation, as amended, following his re-election as a Class II director at the Company’s 2026… Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 16, 2026LeadershipThe Board of Directors of Xilio Therapeutics, Inc., on the recommendation of the Nominating and Corporate Governance committee of the Board, elected Cheryl R. Blanchard, Ph.D., as a Class III director of the Company, with a term expiring at the Company's 2027 annual meeting of stockholders, to… Filing
- Mar 23, 2026ResultsReleased financial results. Filing
- Mar 12, 2026SharesChanged the rights of its shareholders. Filing
- Mar 9, 2026AnnouncementShared information with investors. Filing
- Feb 24, 2026VoteReported shareholder vote results. Filing
- Feb 12, 2026AgreementXilio Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC, as representative of the underwriter named therein, relating to an underwritten offering of pre-funded warrants to purchase up to 74,780,300 shares of common stock at a price to investors of $0.5349 per… Filing
- Jan 8, 2026LeadershipThe Company announced the appointment of Sara M. Bonstein as chair of the Board. Filing
- Jan 5, 2026AnnouncementShared information with investors. Filing
- Nov 25, 2025LeadershipAt the special meeting of stockholders of Xilio Therapeutics, Inc. held on November 21, 2025, the Company’s stockholders approved the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan, which had previously been adopted by the Company’s Board of Directors subject to stockholder approval. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Xilio Therapeutics financials
Famous investors that hold XLO
2 of the 50 well-known investors we track reported holding XLO in their latest 13F filing. The largest position is Jim Simons's, worth $575K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 63,553 | $575K | 0.0% | -1% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 11,061 | $100K | 0.0% | -57% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named XLO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G | 9.3% |
| Nov 16, 2026 | Logos Global Management LP | 13G | 10.0% |
| Nov 16, 2026 | Logos Global Management LP | 13G | 10.0% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G | 9.3% |
| Nov 13, 2026 | Coastlands Capital LP | 13G/A | 10.0% |
| Nov 13, 2026 | Coastlands Capital LP | 13G/A | 10.0% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G | 7.1% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G | 7.1% |
Questions about Xilio Therapeutics, Inc. (XLO) stock
Who owns the most XLO stock?
The largest reported owner of Xilio Therapeutics, Inc. (XLO) is Bain Capital Life Sciences Investors, LLC, with 11.5% of the company. In total, 25 funds and institutions reported holding XLO at the end of Q2 2026, together about 48% of the shares. See the largest owners.
Are XLO insiders buying or selling?
In the last 12 months, XLO insiders reported 1 open-market purchase worth $43.9K and 2 sales worth $5.7K. The latest trade was on Mar 26, 2026. See every trade.
What is the short interest in XLO?
As of Oct 30, 2026, 382,761 XLO shares were sold short, down 4.4% from the report before. At the average daily volume of 18,852 shares, buying them all back would take about 20.3 trading days (days to cover). See the history.
Which famous investors hold XLO?
2 of the 50 well-known investors we track reported XLO in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $575K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.